Cargando…

The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD

BACKGROUND: Immunoglobulin G (IgG) deficiency increases the risk of acute exacerbations and mortality in chronic obstructive pulmonary disease (COPD). However, the impact of IgG subclass deficiency on mortality in COPD is unknown. Here, we determined which IgG subclass, if any, is associated with in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyun, Kovacs, Cara, Mattman, Andre, Hollander, Zsuzsanna, Chen, Virginia, Ng, Raymond, Leung, Janice M., Sin, Don D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158163/
https://www.ncbi.nlm.nih.gov/pubmed/35641962
http://dx.doi.org/10.1186/s12931-022-02052-3
_version_ 1784718780375498752
author Lee, Hyun
Kovacs, Cara
Mattman, Andre
Hollander, Zsuzsanna
Chen, Virginia
Ng, Raymond
Leung, Janice M.
Sin, Don D.
author_facet Lee, Hyun
Kovacs, Cara
Mattman, Andre
Hollander, Zsuzsanna
Chen, Virginia
Ng, Raymond
Leung, Janice M.
Sin, Don D.
author_sort Lee, Hyun
collection PubMed
description BACKGROUND: Immunoglobulin G (IgG) deficiency increases the risk of acute exacerbations and mortality in chronic obstructive pulmonary disease (COPD). However, the impact of IgG subclass deficiency on mortality in COPD is unknown. Here, we determined which IgG subclass, if any, is associated with increased risk of mortality in COPD. METHODS: We measured serum IgG subclass concentrations of 489 hospitalized patients with COPD who were enrolled in the Rapid Transition Program (clinicaltrials.gov identifier NCT02050022). To evaluate the impact of IgG subclass deficiency on 1-year mortality, Cox proportional hazards regression analyses were performed with adjustments for potential confounders. RESULTS: Deficiencies in IgG1, IgG2, IgG3, and IgG4 were present in 1.8%, 12.1%, 4.3%, and 11.2% of patients, respectively. One-year mortality was 56% in patients with IgG1 deficiency, 27% in IgG2 deficiency, 24% in IgG3 deficiency, and 31% in IgG4 deficiency. Cox proportional modeling showed that IgG1 and IgG4 deficiencies increased the 1-year mortality risk with an adjusted hazard ratio of 3.92 (95% confidence interval [CI] = 1.55–9.87) and 1.74 (95% CI = 1.02–2.98), respectively. Neither IgG2 nor IgG3 deficiency significantly increased 1-year mortality. Two or more IgG subclass deficiencies were observed in 5.3%. Patients with 2 or more IgG subclass deficiencies had a higher 1-year mortality than those without any deficiencies (46.2% vs. 19.7%, p < 0.001), with an adjusted hazard ratio of 2.22 (95% CI = 1.18–4.17). CONCLUSIONS: IgG1 and IgG4 deficiency was observed in 1.8% and 11.2% of hospitalized patients with COPD, respectively, and these deficiencies were associated with a significantly increased risk of 1-year mortality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-02052-3.
format Online
Article
Text
id pubmed-9158163
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91581632022-06-02 The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD Lee, Hyun Kovacs, Cara Mattman, Andre Hollander, Zsuzsanna Chen, Virginia Ng, Raymond Leung, Janice M. Sin, Don D. Respir Res Research BACKGROUND: Immunoglobulin G (IgG) deficiency increases the risk of acute exacerbations and mortality in chronic obstructive pulmonary disease (COPD). However, the impact of IgG subclass deficiency on mortality in COPD is unknown. Here, we determined which IgG subclass, if any, is associated with increased risk of mortality in COPD. METHODS: We measured serum IgG subclass concentrations of 489 hospitalized patients with COPD who were enrolled in the Rapid Transition Program (clinicaltrials.gov identifier NCT02050022). To evaluate the impact of IgG subclass deficiency on 1-year mortality, Cox proportional hazards regression analyses were performed with adjustments for potential confounders. RESULTS: Deficiencies in IgG1, IgG2, IgG3, and IgG4 were present in 1.8%, 12.1%, 4.3%, and 11.2% of patients, respectively. One-year mortality was 56% in patients with IgG1 deficiency, 27% in IgG2 deficiency, 24% in IgG3 deficiency, and 31% in IgG4 deficiency. Cox proportional modeling showed that IgG1 and IgG4 deficiencies increased the 1-year mortality risk with an adjusted hazard ratio of 3.92 (95% confidence interval [CI] = 1.55–9.87) and 1.74 (95% CI = 1.02–2.98), respectively. Neither IgG2 nor IgG3 deficiency significantly increased 1-year mortality. Two or more IgG subclass deficiencies were observed in 5.3%. Patients with 2 or more IgG subclass deficiencies had a higher 1-year mortality than those without any deficiencies (46.2% vs. 19.7%, p < 0.001), with an adjusted hazard ratio of 2.22 (95% CI = 1.18–4.17). CONCLUSIONS: IgG1 and IgG4 deficiency was observed in 1.8% and 11.2% of hospitalized patients with COPD, respectively, and these deficiencies were associated with a significantly increased risk of 1-year mortality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-022-02052-3. BioMed Central 2022-05-31 2022 /pmc/articles/PMC9158163/ /pubmed/35641962 http://dx.doi.org/10.1186/s12931-022-02052-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lee, Hyun
Kovacs, Cara
Mattman, Andre
Hollander, Zsuzsanna
Chen, Virginia
Ng, Raymond
Leung, Janice M.
Sin, Don D.
The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD
title The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD
title_full The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD
title_fullStr The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD
title_full_unstemmed The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD
title_short The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD
title_sort impact of igg subclass deficiency on the risk of mortality in hospitalized patients with copd
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9158163/
https://www.ncbi.nlm.nih.gov/pubmed/35641962
http://dx.doi.org/10.1186/s12931-022-02052-3
work_keys_str_mv AT leehyun theimpactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT kovacscara theimpactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT mattmanandre theimpactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT hollanderzsuzsanna theimpactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT chenvirginia theimpactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT ngraymond theimpactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT leungjanicem theimpactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT sindond theimpactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT leehyun impactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT kovacscara impactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT mattmanandre impactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT hollanderzsuzsanna impactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT chenvirginia impactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT ngraymond impactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT leungjanicem impactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd
AT sindond impactofiggsubclassdeficiencyontheriskofmortalityinhospitalizedpatientswithcopd